Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 24, 2018

Primary Completion Date

March 6, 2019

Study Completion Date

March 6, 2019

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

WVE-210201

WVE-210201 is a stereopure antisense oligonucleotide (ASO)

DRUG

Placebo

Sodium Chloride

Trial Locations (13)

9000

UZ Gent, Ghent

20132

U.O. Immunologia Pediatrica, Milan

30318

Rare Disease Research, LLC., Atlanta

98125

U.O.C di Neurologia e Malattie Neuromuscolari Centro Clinico Nemo Sud, Messina

Unknown

Universitaire Ziekenhuizen Leuven, Leuven

CHR de la Citadelle, Liège

London Health Sciences Centre - Hospital, London

Hôpital Armand Trousseau, Paris

University Hospitals Bristol NHS Foundation Trust, Bristol

UCL Institute of Child Health & Great Ormond Street Hospital for Children, London

6525 GC

Radbound University Nijmegen Medical Care, Nijmegen

L12 2AP

Alder Hey Children's Hospital, Liverpool

SE1 7EH

Evelina London Children's Hospital, London

All Listed Sponsors
lead

Wave Life Sciences Ltd.

INDUSTRY

NCT03508947 - Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter